Zava

UK: two own GPhC-registered pharmacies, GMC prescribers, no consultation fee, no subscription. Germany: German patient, Irish Medical Council prescriber, Dutch pharmacy (Prime Pharmacy B.V., Belfeld, KvK 81205864), pass-through drug price plus a flat €33.99 treatment fee. Questionnaire plus photographic BMI verification, asynchronous review, no video. Web only, no app in any market.

Germany: Mounjaro €206.80 to €490.01 by dose plus a flat €33.99 treatment fee, refunded in full if the doctor declines. UK: Mounjaro £169.99 to £309.99 and Wegovy £99.99 to £189.99, no consultation fee and no subscription, which undercuts Juniper UK and Numan at both ends.

Acquired by Hims & Hers, announced 3 June 2025 and completed 1 July 2025. Not all cash despite the press release: roughly €219.2m of accounting consideration made up of €142.2m upfront and €77.0m contingent, plus an earn-out of up to €100m over FY2025 to FY2027. The largest acquired intangible is platform partnerships at $100.2m, the Asda and Superdrug relationships, worth more than technology, customers and brand combined.

1.3 million European and UK customers at acquisition. Health Bridge Limited FY2024 turnover £40,174,544, inside which medication revenue went from £810,382 to £12,992,481 in one year while platform fees stayed flat. 48,380 Trustpilot reviews at 4.8 in Germany, 13,408 at 4.5 in the UK.

Two ASA rulings, both February 2026, one of which held Zava responsible for referral codes its own customers shared and is now precedent. Never named in an MHRA advertising report in twelve years, which is a real negative finding given its competitors are. Named directly in BGH I ZR 114/22 of 9 February 2023, which held Shop Apotheke may not refer patients to Zava under §11 ApoG and §9 HWG, an arrangement trade press reported had restarted in July 2025. The German model itself is now before the CJEU by way of BGH I ZR 118/24 of 26 March 2026.

Zava Deutschland GmbH has been in liquidation since 29 July 2026 while Germany is described as a growth market. Zava UK has been rebuilt as a weight-loss-first, explicitly anti-subscription brand priced against Juniper UK, which the same parent owns.

Announced 3 June 2025, completed 1 July 2025. The press release says one hundred per cent cash at closing. The filings say EUR 219.2m, roughly USD 258.0m, of accounting consideration made up of EUR 142.2m upfront and EUR 77.0m contingent, plus an earn-out of up to EUR 100m over FY2025 to FY2027 and a separate tax-loss reimbursement contingency. A Q1 2026 amendment to the purchase agreement converted about USD 67.0m from contingent to fixed. Anyone modelling Zava off the press release is modelling the wrong number.

Health Bridge Limited FY2024: turnover GBP 40,174,544. Inside that, medication revenue moved from GBP 810,382 to GBP 12,992,481, a sixteenfold increase, while platform fee revenue sat flat at GBP 12,553,814. That looks like a medication-margin story and it is not. Cost of sales grew GBP 12.42m against medication revenue growth of GBP 12.18m, so the implied medication gross margin is between roughly zero and 18 per cent. The real model is GBP 19.50m of consultation and platform fee revenue against GBP 12.99m of medication revenue, which is one pound fifty of fee for every pound of medicine. This corrects our earlier reading. Signed by Laurence Neil Norton, audited by Burgis & Bullock of Leamington Spa on 23 December 2025, which is a small regional firm for a GBP 40m subsidiary of a NYSE issuer and is likely to change.

The largest acquired intangible in the purchase price allocation is platform partnerships at USD 100.2m, which is the Asda and Superdrug relationships. That single line is worth more than the acquired technology, customer relationships and brand combined. Hims did not buy a telemedicine stack. It bought shelf space and a 910-URL German content estate.

No funding round valuation has ever been disclosed for Zava or DrEd. The acquisition price is the only public number.

Anonymous, unauthenticated, no cookie accepted, no age gate, no eligibility interstitial, no login wall. A cold request reaches a full priced product page with a live stock indicator. The brand name, the molecule, the manufacturer, the dose ladder and the price are all visible before any interaction of any kind. The German homepage itself names no brand, but the first click into Gewicht verlieren puts Wegovy, Mounjaro, Saxenda, Nevolat, Xenical and three orlistat products into running body copy and a priced grid.

Exhaustive string search of the raw HTML of the Mounjaro, Wegovy, Wegovy Tabletten, Gewicht verlieren and Abnehmspritzen pages returns zero occurrences of Heilmittelwerbegesetz, zero of HWG, zero of Werbeverbot, zero of Pflichtangaben or Pflichttext, and zero of the standard German Zu Risiken und Nebenwirkungen formula. The only nod to prescription status is the neutral phrase verschreibungspflichtiges Medikament, a downloadable package leaflet, and the line that one of our doctors will assess your request and if appropriate issue a prescription.

The German category stub at /de/abnehmen.html is noindex,nofollow, serves an empty body and is not in the sitemap. A shallow check of the German site lands there and wrongly concludes Zava is HWG-compliant. The real entry point is /de/gewicht-verlieren.html, which is index,follow. Anyone benchmarking German naming discipline needs to go one level deeper than the obvious URL.

Germany 43 brand-named URLs, the UK 71, France 26, Ireland 12, Spain 19. There is no market in which Zava withholds the name. The difference between markets is positioning, not policy. What makes Germany the story is not that Zava names the drugs there but that a sister company under the same owner says in writing that naming them is unlawful.

By Zava Germany’s own published process description the order is: questionnaire, choose your preferred medicine, open a patient account, choose delivery, pay for the medicine plus the 33.99 EUR treatment fee, and only then does a doctor review and decide. Juniper Germany discloses the name at a point equivalent to that last step. The two funnels are near mirror images. Zava refunds all fees including the treatment fee within five to eight days if the doctor declines, which materially softens the payment-first ordering.

Germany inserts a photographic BMI verification step: upload photos of yourself on your first request or after a longer treatment period, with a dedicated photo guidelines page. That is a meaningfully stronger clinical control than self-declared BMI and it is the direct answer to the GPhC’s November 2025 finding against the UK pharmacy, which was that verification does not include independently verifying the person’s height so the BMI may not always be accurate. The German business already does what the UK inspector asked for.

Live properties are /uk/, /de/, /fr/, /ie/ and /es/ on one domain. zavamed.de redirects to /de/. www.dred.com, the original DrEd domain, redirects to the German site rather than the UK one, which is a small but telling artefact of where the content equity actually sits. dred.de does not exist. zavamed.fr, .es, .ie, .at and .ch are all NXDOMAIN. There is no Austrian, Swiss or Italian consumer property.

79 unique DNS names. The conventional guesses, app, my, account, cdn, admin, blog, help, staging and dev, are all NXDOMAIN. The real estate uses its own conventions: pharmacy-service, pharmacy-hub, dispatch, consultation-triage, clinical-rules, signer, consent-policies and a set of EHR admin hosts. Per-market admin instances exist for uk, de, fr, ie, es and it. The Italian one has no consumer property behind it. gkv.zavamed.com, named for German statutory health insurance, now redirects to an app support page. Internal tooling visible in the logs includes Okta, Temporal, Lightdash, Zulip and services named forge, kirin, jarvis, marc-admin and fractl.

DE 910, FR 416, UK 343, IE 153, ES 64. Germany is 2.7 times the UK, which inverts the commercial picture, because the UK is the weight-loss-led market. German depth is a legacy DrEd asset built since 2011. Weight loss is only 8 per cent of the German estate but 27 per cent of the UK one and 41 per cent of the Spanish one. Last-modified dates cluster on 19 and 20 August 2026, so the whole estate is actively maintained.

Brand hub then attribute spokes (dosierung, nebenwirkungen, absetzen, haarausfall, und-alkohol). Brand versus brand comparisons. Switching pages that map exactly onto the UK homepage poaching door. Side-effect capture pages including ozempic-face, ozempic-butt, ozempic-mouth and ozempic-feet. Cost and access intent. And regulatory-edge intent including ozempic-rezeptfrei and abnehmspritzen-generika. The gap: there are no named-competitor pages anywhere in any sitemap. Zava competes brand against brand, never company against company. A rival that builds comparison pages against Zava faces no defensive content at all.

There is no Google Tag Manager, no GA4, no Meta Pixel, no TikTok pixel and no Bing UET in the delivered HTML of either homepage. Everything routes through Segment proxied first-party on their own domain at av1.zavamed.com, with SiteSpect for A/B testing server-side, OneTrust self-hosted for consent, New Relic for RUM and Cloudinary for images. That architecture defeats ad blockers and cookie truncation, keeps vendor fan-out behind consent, and minimises third-party surface on pages carrying prescription-medicine content. Competitors on client-side GTM plus Meta Pixel are measuring a materially worse signal.

One robots.txt for all five markets, 724 bytes. It carefully disallows /api/, /search/, /assessment/, /account/ and /auth/ for each market. It contains zero directives for GPTBot, CCBot, ClaudeBot, Google-Extended, PerplexityBot, Bytespider, Applebot-Extended or anthropic-ai. Every AI crawler is permitted across all 1,886 URLs, including the 43 German brand pages. For a regulated healthcare business in 2026 that is a striking omission next to the care taken over the funnel paths.

The Apple App Store returns no Zava telehealth app for GB or DE. The Google Play listing com.zavamed.zava has been removed and survives only on APK mirrors, the usual signature of a delisting. Zava confirms it directly: the video consultation offering via the ZAVA app is currently paused. Germany substitutes a third-party app, MyTherapy, linked from the GLP-1 pages. Competitors running retention through a first-party app hold a structural adherence and lifetime-value advantage that Zava has actively given up.

Zava Germany: 4.8 on 48,380 reviews, 89.6 per cent five star, 2.5 per cent one star. Zava UK: 4.5 on 13,408 reviews, 80.3 per cent five star, 10.5 per cent one star. The UK one-star rate is 4.2 times the German one on a third of the volume. Both figures are read from the Trustpilot JSON payload, not from rendered text, and both match the JSON-LD the sites publish about themselves, which is honest practice.

There is a second, near-empty UK profile at uk.trustpilot.com/review/zavamed.com showing 3.2 from three reviews, claimed March 2025, listing a Torrens Street EC1V 1NY address. Anyone benchmarking Zava UK from the obvious URL reads 3.2 out of three instead of 4.5 out of 13,408.

Response time is the single topic Trustpilot marks ambiguous in the UK; every other topic is positive. The substantive complaints are cold-chain failures on GLP-1s delivered by Royal Mail in hot weather, with at least one customer reporting a three-month supply spoiled, and faulty pens with refund friction. In Germany the complaints are structurally different and milder: prescriptions processed around midday rather than before the pharmacy opens, and DHL Express not giving a delivery window. Both markets reply to about 99 per cent of negative reviews, typically within a day, and both disclose that replies may be AI-assisted.

Germany: DoktorABC 4.7 on 49,830, Zava DE 4.8 on 48,380, Voy Deutschland 4.7 on 5,063, MedExpress DE 4.6 on 2,078, Juniper Deutschland 4.6 on 2,479. Zava Germany has roughly twenty times Juniper Germany’s review volume at a higher score. United Kingdom: Zava UK 4.5 on 13,408 against Juniper UK 4.5 on 13,457, an almost exact match on both score and volume, with Numan 4.6 on 36k, Voy UK 4.7 on 25,169 and Bolt 4.5 on 5,994 around them.

In Germany the brand that names the drugs is twenty times larger in consumer footprint than the sister brand that refuses to. That asymmetry is why the contradiction is unlikely to resolve quietly in Juniper’s favour, and it is the single most important thing to understand before deciding which German naming posture to copy.